Increased serum type I interferon activity in organ-specific autoimmune disorders: Clinical, imaging, and serological associations

Frontiers in Immunology

Volumn 4, Issue AUG, 2013, Pages

  Mavragani, Clio P ^a,b   Niewold, Timothy B ^c   Chatzigeorgiou, Antonis ^b   Danielides, Stamatina ^b,d   Thomas, Dimitrios ^b   Kirou, Kyriakos A ^a   Kamper, Elli ^b   Kaltsas, Grigorios ^b   Crow, Mary K ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c MAYO GRADUATE SCHOOL   (United States)

^d NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Autoimmune thyroid disease; Organ specific autoimmunity; Type I diabetes; Type I interferon

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; AUTOANTIBODY; C REACTIVE PROTEIN; CHOLESTEROL; HEMOGLOBIN A1C; INTERFERON; THYROGLOBULIN; THYROTROPIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; AUTOIMMUNITY; CELL ASSAY; CLINICAL FEATURE; CONTROLLED STUDY; ECHOGRAPHY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; GENE; GENE EXPRESSION; GENOTYPING TECHNIQUE; HUMAN; IMMUNOASSAY; INSULIN DEPENDENT DIABETES MELLITUS; INTERFERON INDUCED HELICASE 1 GENE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATHOGENESIS; PREVALENCE; SEROLOGY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID FUNCTION TEST;

EID: 84883699617     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00238     Document Type: Article

References (48)

1. Weetman AP. Determinants of autoimmune thyroid disease. Nat Immunol (2001) 2(9):769-70. doi:10.1038/ni0901-769
2. La Torre D. Immunobiology of beta-cell destruction. Adv Exp Med Biol (2012) 771:194-218.
3. Caturegli P, Kimura H, Rocchi R, Rose NR. Autoimmune thyroid diseases. Curr Opin Rheumatol (2007) 19(1):44-8. doi:10.1097/BOR.0b013e3280113d1a
4. Anaya JM, Castiblanco J, Tobon GJ, Garcia J, Abad V, Cuervo H, et al. Familial clustering of autoimmune diseases in patients with type 1 diabetes mellitus. J Autoimmun (2006) 26(3):208-14. doi:10.1016/j.jaut.2006.01.001
5. Crow MK. Type I interferon in organ-targeted autoimmune and inflammatory diseases. Arthritis Res Ther (2010) 12(Suppl 1):S5. doi:10.1186/ar2886
6. Mavragani C, Danieledes SI, Moutsopoulos HM. Systemic autoimmune manifestations: when should underlying thyroid autoimmunity be considered? Curr Rheumatol Rev (2005) 2(4):345-8. doi:10.2174/157339706778699832
7. Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG, et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum (2004) 50(12):3958-67. doi:10.1002/art.20798
8. Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci U S A (2006) 103(8):2770-5. doi:10.1073/pnas.0510837103
9. Smyth DJ, Cooper JD, Bailey R, Field S, Burren O, Smink LJ, et al. A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat Genet (2006) 38(6):617-9. doi:10.1038/ng1800
10. Sutherland A, Davies J, Owen CJ, Vaikkakara S, Walker C, Cheetham TD, et al. Genomic polymorphism at the interferon-induced helicase (IFIH1) locus contributes to Graves' disease susceptibility. J Clin Endocrinol Metab (2007) 92(8):3338-41. doi:10.1210/jc.2007-0173
11. Foy E, Li K, Sumpter R Jr, Loo YM, Johnson CL, Wang C, et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci U S A (2005) 102(8):2986-91. doi:10.1073/pnas.0408707102
12. Salloum R, Franek BS, Kariuki SN, Rhee L, Mikolaitis RA, Jolly M, et al. Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients. Arthritis Rheum (2010) 62(2):553-61. doi:10.1002/art.27182
13. Robinson T, Kariuki SN, Franek BS, Kumabe M, Kumar AA, Badaracco M, et al. Autoimmune disease risk variant of IFIH1 is associated with increased sensitivity to IFN-alpha and serologic autoimmunity in lupus patients. J Immunol (2011) 187(3):1298-303. doi:10.4049/jimmunol.1100857
14. Fabris P, Betterle C, Floreani A, Greggio NA, de Lazzari F, Naccarato R, et al. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet (1992) 340(8818):548. doi:10.1016/0140-6736(92)91744-S
15. Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Archimandritis AJ. Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol (2007) 13(8):1292-4.
16. Caruso G, Attard M, Caronia A, Lagalla R. Color Doppler measurement of blood flow in the inferior thyroid artery in patients with autoimmune thyroid diseases. Eur J Radiol (2000) 36(1):5-10. doi:10.1016/S0720-048X(00)00147-9
17. Yagyu H, Okada K, Sato S, Yamashita Y, Okada N, Osuga J, et al. Pegylated interferon-alpha2b and ribavirin combination therapy induces Hashitoxicosis followed by type 1 diabetes mellitus. Diabetes Res Clin Pract (2012) 95(3):e52-4. doi:10.1016/j.diabres.2011.11.016
18. Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology (2006) 43(4):661-72. doi:10.1002/hep.21146
19. Chatzigeorgiou A, Harokopos V, Mylona-Karagianni C, Tsouvalas E, Aidinis V, Kamper EF. The pattern of inflammatory/anti-inflammatory cytokines and chemokines in type 1 diabetic patients over time. Ann Med (2010) 42(6):426-38. doi:10.3109/07853890.2010.495951
20. Mavragani CP, Niewold TB, Moutsopoulos NM, Pillemer SR, Wahl SM, Crow MK. Augmented interferon-alpha pathway activation in patients with Sjogren's syndrome treated with etanercept. Arthritis Rheum (2007) 56(12):3995-4004. doi:10.1002/art.23062
21. Banaka I, Kaltsas G, Antoniou S, Kanakis G, Zilos A, Baltas CS, et al. Prognostic value of vascularity index for the diagnosis of autoimmune thyroid disease. JBR-BTR (2011) 94(4):185-90.
22. Hua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum (2006) 54(6):1906-16. doi:10.1002/art.21890
23. Stefan M, Jacobson EM, Huber AK, Greenberg DA, Li CW, Skrabanek L, et al. Novel variant of thyroglobulin promoter triggers thyroid autoimmunity through an epigenetic interferon alpha-modulated mechanism. J Biol Chem (2011) 286(36):31168-79. doi:10.1074/jbc.M111.247510
24. Akeno N, Smith EP, Stefan M, Huber AK, Zhang W, Keddache M, et al. IFN-alpha mediates the development of autoimmunity both by direct tissue toxicity and through immune cell recruitment mechanisms. J Immunol (2011) 186(8):4693-706. doi:10.4049/jimmunol.1002631
25. Somers EC, Zhao W, Lewis EE, Wang L, Wing JJ, Sundaram B, et al. Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS ONE (2012) 7(5):e37000. doi:10.1371/journal.pone.0037000
26. Thacker SG, Zhao W, Smith CK, Luo W, Wang H, Vivekanandan-Giri A, et al. Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis Rheum (2012) 64(9):2975-85. doi:10.1002/art.34504
27. Yeh HC, Futterweit W, Gilbert P. Micronodulation: ultrasonographic sign of Hashimoto thyroiditis. J Ultrasound Med (1996) 15(12):813-9.
28. Mavragani CP, Crow MK. Activation of the type I interferon pathway in primary Sjogren's syndrome. J Autoimmun (2010) 35(3):225-31. doi:10.1016/j.jaut.2010.06.012
29. Fentiman IS, Thomas BS, Balkwill FR, Rubens RD, Hayward JL. Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet (1985) 1(8438):1166. doi:10.1016/S0140-6736(85)92475-4
30. Custro N, Montalto G, Scafidi V, Soresi M, Gallo S, Tripi S, et al. Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy. J Endocrinol Invest (1997) 20(7):374-80.
31. Nagayama Y, Ohta K, Tsuruta M, Takeshita A, Kimura H, Hamasaki K, et al. Exacerbation of thyroid autoimmunity by interferon alpha treatment in patients with chronic viral hepatitis: our studies and review of the literature. Endocr J (1994) 41(5):565-72. doi:10.1507/endocrj.41.565
32. Kawashima A, Yamazaki K, Hara T, Akama T, Yoshihara A, Sue M, et al. Demonstration of innate immune responses in the thyroid gland: potential to sense danger and a possible trigger for autoimmune reactions. Thyroid (2013) 23(4):477-87. doi:10.1089/thy.2011.0480
33. Nonchev BI. Cases of interferon-alpha and interferon-beta-induced thyroiditis. Folia Med (Plovdiv) (2010) 52(3):5-12.
34. Rotondi M, Stufano F, Lagonigro MS, La Manna L, Zerbini F, Ghilotti S, et al. Interferon-beta but not Glatiramer acetate stimulates CXCL10 secretion in primary cultures of thyrocytes: a clue for understanding the different risks of thyroid dysfunctions in patients with multiple sclerosis treated with either of the two drugs. J Neuroimmunol (2011) 234(1-2):161-4. doi:10.1016/j.jneuroim
35. Kuang M, Wang S, Wu M, Ning G, Yao Z, Li L. Expression of IFNalpha-inducible genes and modulation of HLA-DR and thyroid stimulating hormone receptors in Graves' disease. Mol Cell Endocrinol (2010) 319(1-2):23-9. doi:10.1016/j.mce.2009.12.006
36. Kobawala TP, Patel GH, Gajjar DR, Patel KN, Thakor PB, Parekh UB, et al. Clinical utility of serum interleukin-8 and interferon-alpha in thyroid diseases. J Thyroid Res (2011) 2011:270149. doi:10.4061/2011/270149
37. Hammerstad SS, Jahnsen FL, Tauriainen S, Hyoty H, Paulsen T, Norheim I, et al. Inflammation and increased myxovirus resistance protein A expression in thyroid tissue in the early stages of Hashimoto's thyroiditis. Thyroid (2013) 23(3):334-41. doi:10.1089/thy.2012.0264
38. Stewart TA, Hultgren B, Huang X, Pitts-Meek S, Hully J, MacLachlan NJ. Induction of type I diabetes by interferon-alpha in transgenic mice. Science (1993) 260(5116):1942-6. doi:10.1126/science.8100367
39. Chehadeh W, Weill J, Vantyghem MC, Alm G, Lefebvre J, Wattre P, et al. Increased level of interferon-alpha in blood of patients with insulin-dependent diabetes mellitus: relationship with coxsackievirus B infection. J Infect Dis (2000) 181(6):1929-39. doi:10.1086/315516
40. Huang X, Yuang J, Goddard A, Foulis A, James RF, Lernmark A, et al. Interferon expression in the pancreases of patients with type I diabetes. Diabetes (1995) 44(6):658-64. doi:10.2337/diabetes.44.6.658
41. Devendra D, Eisenbarth GS. Interferon alpha - a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity. Clin Immunol (2004) 111(3):225-33. doi:10.1016/j.clim.2004.01.008
42. McCartney SA, Vermi W, Lonardi S, Rossini C, Otero K, Calderon B, et al. RNA sensor-induced type I IFN prevents diabetes caused by a beta cell-tropic virus in mice. J Clin Invest (2011) 121(4):1497-507. doi:10.1172/JCI44005
43. Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA (2012) 307(12):1302-9. doi:10.1001/jama.2012.366
44. Martin SS, Qasim AN, Mehta NN, Wolfe M, Terembula K, Schwartz S, et al. Apolipoprotein B but not LDL cholesterol is associated with coronary artery calcification in type 2 diabetic whites. Diabetes (2009) 58(8):1887-92. doi:10.2337/db08-1794
45. Vazquez N, Schmeisser H, Dolan MA, Bekisz J, Zoon KC, Wahl SM. Structural variants of IFNalpha preferentially promote antiviral functions. Blood (2011) 118(9):2567-77. doi:10.1182/blood-2010-12-325027
46. Argyris EG, Acheampong E, Wang F, Huang J, Chen K, Mukhtar M, et al. The interferon-induced expression of APOBEC3G in human blood-brain barrier exerts a potent intrinsic immunity to block HIV-1 entry to central nervous system. Virology (2007) 367(2):440-51. doi:10.1016/j.virol.2007.06.010
47. Kaplan MJ, Salmon JE. How does interferon-alpha insult the vasculature? Let me count the ways. Arthritis Rheum (2011) 63(2):334-6. doi:10.1002/art.30161
48. Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun (2007) 8(6):492-502. doi:10.1038/sj.gene.6364408